Capsida Receives FDA Fast Track Designation for Its Potential First-in-Class IV-Administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy
Publisher
Capsida Biotherapeutics
Limited excerpt on-platform. Click anywhere on this card to open the original publisher in a new tab.
Canonical metadata stays public, while full text remains on the original site.